Wonrak Son
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
High-dimensional immune profiling of peripheral blood identifies immune correlates of anti-PD-1/PD-L1 resistance in oncogenic driver mutation-positive NSCLC.
Journal: Frontiers in immunology
Published: March 13, 2026
EpCAM+ Extracellular Vesicle PD-L1 Dynamics as a Predictive Biomarker of Immune Checkpoint Blockade Response.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: January 14, 2026
A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma.
Journal: Oral oncology
Published: July 22, 2025
Circulating Tumor Cell-based Molecular Responses Stratify EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Cancer.
Journal: Cancer research and treatment
Published: June 29, 2025
4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy.
Journal: Cell reports. Medicine
Published: April 07, 2025
Comparative single-cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses.
Journal: Cancer communications (London, England)
Published: February 07, 2025
Preclinical investigation of anti-tumor efficacy of allogeneic natural killer cells combined with cetuximab for head and neck squamous cell carcinoma.
Journal: Cancer immunology, immunotherapy : CII
Published: December 10, 2024
Showing 1-9 of 9
Last Updated: 09/26/2026